Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C Payer Insight: Update Bulletin [April 2015]

Product Code:
596200346
Release Date:
April 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Hepatitis C.  Topics covered: withdrawal of Victrelis (boceprevir), Merck’s grazoprevir/elbasvir combination, AbbVie’s ABT-493/ABT-530 regimen, Gilead’s decision to offer rebates and discounts of up to 46%, payer adoption of daclatasvir, effect of the United Health merger with Catamaran, patient adherence in HCV.

Key Questions Answered in this Update Bulletin:

  • How significant is Merck & Co.’s decision to withdraw Victrelis (boceprevir) from the US market by the end of 2015?
  • Will Merck’s grazoprevir/elbasvir combination be able to find a niche in the HCV market?
  • Are payers likely to view the potential for shorter treatment duration with AbbVie’s ABT-493/ABT-530 regimen favourably?
  • What effects will Gilead’s decision to offer rebates and discounts of up to 46% have on the HCV market in 2015?
  • Assuming FDA approval, what will Bristol-Myers Squibb need to do to drive payer adoption of daclatasvir in an increasingly competitive market?
  • What is the likely effect of the United Health merger with Catamaran on the HCV market?
  • Could recently published trial data from studies in HCV/HIV co-infected patients potentially change the treatment dynamics in this patient group?
  • What are the main concerns for payers with regard to patient adherence in HCV?
  • Is the dramatic increase in spending on HCV therapy in 2014 likely to be repeated this year?

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved